By physician referral or invitation only

Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Individuals with Refractory Focal Onset Epilepsy

The purpose of this study is to assess the efficacy of BHV-7000 over the course of a 104 week trial with a two-week follow up phase totalling 106 weeks. Individuals must have been enrolled in the parent BHV-7000-303 study to qualify for this study.

Age & Gender

18 years ~ 70 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Lynn Liu
Neurology-Epilepsy

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System

IRB Number

25-0504

ClinicalTrials.gov

NCT06443463

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.